Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier, HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for surgical patients, has the ability to restore tissue oxygenation in persistently ischemic tissue. The development of this new class of compounds, referred to as oxygen therapeutics, provides an opportunity to test the safety and efficacy of a new approach to management of myocardial ischemia.
Epistemonikos ID: 2aed72ea3d90dce93aa8da65dae279e8a2cfaf15
First added on: May 04, 2024